In response to the criticism that the prior review approval rate of certain drugs is low, the Health Insurance Review and Assessment Service said that the low rate is due to a lack of understanding of the reimbursement standards and that it will maintain the current standards.

The response was made regarding the low approval rate of Soliris for aHUS (atypical hemolytic uremic syndrome) disease.

On the 18th, Rep. Sun-Woo Kang of the Democratic Party of Korea made a written inquiry about the low prior approval rate of certain drugs used for aHUS during the NA audit of the Health Insurance Review and Assessment Service.

aHUS is a severe and rare hereditary disease in